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Liangbiao Chen,5 Ming Zhang,2 and Y. Eugene Chen1
Smooth muscle cell (SMC) differentiation and dedifferentiation play a critical role in the pathogenesis of cardio-
vascular diseases. The lack of a good and simple in vitro SMC differentiation system has hampered the progress 
of SMC fi eld for years. The generation of such an in vitro system would be invaluable for exploring molecular 
mechanisms of SMC differentiation and dedifferentiation. Recently, the establishment of induced pluripotent 
stem (iPS) cells has offered a novel therapeutic strategy to generate patient-specifi c stem cell lines. Here we have 
investigated whether iPS cells are able to differentiate into SMCs in vitro. Mouse iPS cell (O9 and TT025) mono-
layers were treated with 10−5 mol/L all-trans retinoid acid (RA). After 8 days of RA treatment, we found that 
>40% of the O9 iPS cells expressed the SMC-markers including SMα-actin and SM myosin heavy chain. Also, 
we documented that iPS-derived SMCs acquired SMC functional characteristics including contraction and cal-
cium infl ux in response to stimuli. Moreover, our results indicated that there were differences in SMC-specifi c 
gene expression patterns between SMCs derived from O9 and TT025 iPS as well as normal embryonic stem cells. 
These differences might be due to disparity in the current iPS technology. Taken together, our data have estab-
lished a simple iPS-SMC system to generate SMCs in vitro, which has tremendous potential to generate individ-
ualized SMCs for vascular tissue engineering and personalized drug screening.
Introduction
Induced pluripotent stem (iPS) cell techniques provide a way to generate targeted and individualized cell lines 
from a patient’s own tissues [1–4], and show promising ther-
apeutic potential [5–6], smooth muscle cell (SMC) differenti-
ation and dedifferentiation are implicated in a large number 
of major diseases, including atherosclerosis, hypertension, 
and cancer [7–9]. The molecular mechanisms of SMC differ-
entiation and dedifferentiation are poorly understood due 
to the lack of a good SMC differentiation in vitro model. The 
development of a system to recapitulate SMC differentiation 
in vitro, would contribute to novel cell-based therapies for 
SMC-related diseases [10,11]. Our previous work has shown 
that all-trans retinoid acid (RA) can be used to drive the dif-
ferentiation of human embryonic stem (ES) cells into SMCs 
using an embryoid body (EB)-independent method [12]. In 
this study, we document that some iPS cell lines exhibit 
similar features to ES cells in terms of SMC differentiation 
in vitro. Differentiation of iPS cells into SMC in vitro pro-
vides a novel cell model system to study molecular mecha-
nisms of SMC-related diseases and generate individualized 




Mouse iPS cells (O9 and TT025, kindly provided by 
Dr. Jaenisch at the Massachusetts Institute of Technology) 
[3] and mouse ES cells (including B6-white, CMTI-1, and 
CMTI-2) were routinely cultured on tissue culture plates 
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coated with 0.1% gelatin (Sigma-Aldrich, St. Louis, MO, 
USA) in Dulbecco’s modifi ed Eagle’s medium (DMEM)/F12 
(Invitrogen, Carlsbad, CA, USA) in the presence of 15% ES 
cell–qualifi ed fetal bovine serum (Hyclone, Logan, UT, USA), 
0.1 mmol/L 2-mercaptoethanol, 1 mmol/L l-glutamine, 
0.1 mmol/L nonessential amino acids, penicillin, and strep-
tomycin (Invitrogen, Carlsbad, CA, USA) and 1,000 U/mL 
murine LIF (Chemicon International, Temecula, CA, USA). 
Cells were trypsinized and replated or refed every second 
day. For directed differentiation of mouse iPS and ES cells to 
SMCs, mouse embryonic fi broblasts were fi rst isolated from 
undifferentiated mouse ES cells as previously described 
[12]. The resuspended single mouse ES and iPS cells were 
plated on 6-well, gelatin-coated plastic petri dishes (Falcon, 
BD Bioscience, Bedford, MA, USA) with a density of ~4 × 
104/cm2 at 37°C, 5% CO2 in differentiation medium. The 
differentiation medium consisted of DMEM/F12, 10% fetal 
calf serum, 1 mmol/L l-glutamine, 0.1 mmol/L 2-mercap-
toethanol, 0.1 mmol/L nonessential amino acids, penicillin, 
and streptomycin with the supplemental of 10−5 mol/L all-
trans RA (Sigma-Aldrich, St. Louis, MO, USA). The culture 
was continued for 8–10 days with a daily change of fresh 
RA-containing differentiation media.
Immunocytochemistry
Derived cells were trypsinized with TrypLETM Express 
for 5 min. Afterward, cells were resuspended in differen-
tiation medium and plated on 0.1% gelatin-coated chamber 
polystyrene vessels (BD Bioscience, Bedford, MA, USA) and 
incubated in differentiation medium. Cells were then fi xed 
and permeabilized using BD cytofi x/cytopermTM kit (BD 
Bioscience, Bedford, MA, USA), and incubated overnight 
with the primary antibodies, mouse anti-smooth muscle 
(SM)-α-actin 1:1,000 (Chemicon International, Temecula, 
CA) and rabbit anti-SM myosin heavy chain (SMMHC) 1:300 
(Biomedical Technologies Inc., Stoughton, MA). After rins-
ing, secondary goat anti-mouse or rabbit immunoglobulin 
G (IgG) alexa fl uor 594 (red) or 488 (green) 1:500 (Molecular 
Probes, Eugene, OR, USA) were added to the samples, 
which were then incubated for an additional hour. The cell 
nuclei were stained with 4’-6-Diamidino-2-phenylindole 
(Molecular Probes, Eugene, OR, USA). Finally, the cells 
were rinsed once more and mounted with mounting media. 
The slides were analyzed using fl uorescence microscopy 
(Olympus, Japan). Normal mouse IgG1 and IgG2a (DAKO 
Corporation, Carpinteria, CA, USA) served as the negative 
control for SMMHC and SM-α-actin primary antibodies, 
respectively.
Fluorescence-activated cell-sorting analysis
After derived differentiated cells were resuspended in 
differentiation medium and centrifuged, the pellets were 
fi xed and permeabilized using a BD cytofi x/cytopermTM kit 
and incubated overnight with the primary antibody. Mouse 
IgG1 or IgG2a served as isotypic controls, whereas 293 cells 
and rat vascular SMCs served as the negative and positive 
controls, respectively. Secondary goat anti-mouse IgG alexa 
fl uor 488 (Molecular Probes, Eugene, OR, USA) was added 
to the samples, which were then incubated for an additional 
hour. Finally, the cells were rinsed once more and fl uores-
cence was analyzed using the FACSCaliburTM system (BD 
Biosciences, San Jose, CA, USA) following the user’s guide.
qRT-PCR
Total RNA from dimethyl sulfoxide (DMSO)- or RA-treated 
cells was extracted by using the RNeasy mini kit (Qiagen, 
Valencia, CA, USA) according to the manufacturer’s instruc-
tions. Complementary DNA (cDNA) was synthesized from 
5 μg of total RNA with a superscript III fi rst-strand synthe-
sis system (Invitrogen, Carlsbad, CA, USA). cDNA samples 
were subjected to PCR amplifi cation with primers specifi c 
for mouse SMC genes and other control genes. PCR prim-
ers and reaction conditions are described in Supplementary 
Table 1 (Supplementary Table is available online at http://
www.liebertpub.com/scd). 18S rRNA served as an internal 
standard. The value of the threshold cycle of each reaction 
was compared.
Western blot analysis
Protein samples were extracted using the M-PER mam-
malian protein extraction reagent (Pierce, Rockford, IL) 
supplemented with a protease inhibitor cocktail (Roche 
Diagnostics, Indianapolis, IN). Antibodies against SM-α-
actin (1:2,000 dilution, Chemicon International, Temecula, 
CA, USA), SMMHC (1:3,000 dilution, Biomedical Technologies 
Inc., Stoughton, MA, USA), and β-tubulin (1:10,000 dilu-
tion, Upstate, Charlottesville, VA, USA) were used for test-
ing SMC-specifi c protein expression. Immunoactivity was 
visualized by the enhanced chemiluminescence’s detection 
system (ECL, Amersham Biosciences, Pittsburg, PA, USA) 
according to the manufacturer’s instructions.
FIG. 1. Mouse iPS cells can be induced to SMC differentiation by RA treatment. (A) Immunostaining of SMC-like cells 
derived from O9 iPS (upper panel) and CMTI-1 ES cells (lower panel) with SMC-specifi c markers, SMMHC (left panel, green) 
and SM-α-actin (right panel, red). The nuclei (blue) were costained with DAPI. Bar = 10 μm. (B) FACS analysis showing rep-
resentative expression of SMMHC in SMC-like cells derived from O9 iPS and CMTI-1 ES cells at Day 8 of the treatment. 
SMMHC-positive cells signifi cantly increased in O9 iPS and CMTI-1 ES cells after treatment with 10−5 mol/L RA for 8 days 
(mouse iPS cells: 41.26 ± 2.15%; CMTI-1 ES cells: 50.33 ± 3.07%), whereas the spontaneous differentiated (DMSO treated) cells 
displayed lower SMMHC-positive numbers (O9 iPS cells: 5.92 ± 0.94%; CMTI-1 ES cells: 9.32 ± 1.02%, n = 3, P < 0.05). Left 
panel shows negative control from cells with normal mouse IgG 1 as primary antibody, right-upper panel shows SMMHC-
positive cell analysis from O9 iPS cells, right-lower panel from CMTI-1 ES cells. (C) Representative western blots showing 
SMC-specifi c proteins from O9 iPS-derived SMCs. CMTI-1 ES cell–derived SMCs served as positive control. β-tubulin was 
used as the loading control.
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Contractility assays
Agonist-induced contractile activity of the differenti-
ated cells was assayed as previously described [13]. Derived 
 differentiated cells with DMSO- or RA treatment were 
washed with phosphate-buffered saline (PBS), stimulated 
with 1 mmol/L carbachol (Sigma-Aldrich, St. Louis, MO, 
USA) in the differentiation medium and monitored under 
the microscope for 5 min. Images of the same fi eld before 
and after carbachol treatment were snapped and compared.
Measurement of physiological responses
SMCs derived from mouse ES and iPS cells were cul-
tured on a 35-mm circular coverslip and loaded with the 
calcium-sensitive fl uorophore, Fluo-4 AM (2.5 μmmol/L; 
Molecular Probes, Eugene, OR, USA), and mounted into a 
constant-fl ow superfusion chamber as previously described 
[14]. Observation of intracellular Ca2+ changes was per-
formed with confocal microscope (LSM 510 Meta, Carl 
Zeiss MicroImaging Inc, Thornwood, NY, USA). Fluo-4 was 
excited at 490 nm by a mercury arc lamp, and fl uorescence 
emission was measured at 528 nm.
Statistical analysis
All data, calculated as a percentage from three indepen-
dent experiments, were expressed as the mean ± SD and 
were evaluated with a χ2 test. A value of P < 0.05 was con-
sidered statistically signifi cant.
Results
We have previously shown that human ES cells were able 
to differentiate into SMCs in response to the RA treatment 
using an EB-independent method [12]. In this study, we set 
out to determine whether iPS cells could also differentiate 
into SMCs in response to RA treatment in vitro. Mouse ES 
cells as well as iPS cells O9 and TT025 were induced to dif-
ferentiate into SMCs following the protocol shown in Sup-
plementary Fig. S1A (Supplementary Figure is available 
online at http://www.liebertpub.com/scd). We fi rst tested 
this protocol using mouse ES cells. The results showed that, 
for mouse ES cells, the differentiation effi ciency into SMC 
induced with this protocol was dose-dependent on the RA 
concentration, as shown with SM-α-actin and SMMHC 
 expression by quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR) and western blot-
ting (Supplementary Fig. S1B–D). Under treatment with 
10−5 mol/L RA, the O9 iPS cell monolayers underwent dra-
matic morphological changes (data not shown) similar to 
as the change observed for mouse ES cells. The single cells 
 acquired a fi brous-like shape starting from day 2. Gradually, 
the fi brous-like cells would dominate the culture from day 
5 on and become confl uent with a signifi cant morphologi-
cal difference compared with the vehicle (DMSO)-treated 
cell population, which showed random cell types (data not 
shown). As a result, a morphologically homogeneous cell 
population was achieved, which can be maintained in pro-
longed culture time. Intriguingly, TT025 iPS cells, when 
treated with 10−5 mol/L RA, died before day 4, instead of 
differentiation.
O9 iPS cells treated with 10−5 mol/L RA for 8 days dis-
played SMMHC and SM-α-actin expression as deter-
mined by  immunofl uorescence (Fig. 1A), similar to the 
expression  observed in mouse ES cells. Fluorescence-
activated cell-sorting (FACS) analysis was performed with 
anti-SMMHC  antibody to further assess the degree of 
homogeneity of SMC differentiation. As shown in Fig. 1B, 
SMMHC-positive cells signifi cantly increased in both O9 
iPS and ES cells after treatment with RA for 8 days, when 
compared to vehicle-treated spontaneous differentiation 
(O9 iPS cells: 41.26 ± 2.15% vs. 5.92 ± 0.94%, n = 3, P < 0.05, 
mouse ES cells: 50.33 ± 3.07% vs. 9.32 ± 1.02%). In parallel, 
western blot analyses  demonstrated that expression lev-
els of SM-α-actin and SMMHC proteins were upregulated 
in a time dependent-manner in RA-treated O9 iPS cells, 
although the fi nal SMMHC levels was different between 
mouse ES and O9 iPS cells (Fig. 1C). To confi rm the western 
blot data, the expression of SMC-specifi c genes was deter-
mined by qRT-PCR to demonstrate the effect of culture 
conditions on SMC differentiation (Fig. 2). A SMC-specifi c 
transcriptional coactivator (Myocardin), intermediate stage 
markers (SM22α and SM-α-actin), and a late stage marker 
(SMMHC) were signifi cantly upregulated in RA-treated 
mouse ES and O9 iPS cells. Simultaneously, there was an 
obvious downregulation of markers of undifferentiated ES 
cells (Oct4 and Nanog) (data not shown). In addition, genes 
specifi cally expressed in cardiomyocytes (cTnI), endothe-
lial cells (PECAM-1), and skeletal myocytes (MCKM) were 
maintained at low levels during this RA-induced SMC dif-
ferentiation process (Supplementary Fig. S2). Moreover, 
endogenous or total expression level of Oct4, Klf4, Sox2, 
and c-Myc, which had been used for generation of iPS cell 
lines, were tested by using specifi c primers [2] during O9 
iPS cell differentiation and showed that most transcripts of 
these four transcription factors originated from the endog-
enous locus rather than the viral vector, except c-Myc (Sup-
plementary Fig. S3).
Contraction in response to stimuli, which is a requisite 
characteristic of mature SMCs was checked separately in 
differentiated cells from mouse ES and O9 iPS cells derived 
from this protocol. These derived SMCs were treated with 
carbachol (1 mmol/L), and monitored for 10 min under the 
microscope (Fig. 3, O9 iPS-derived SMC, mouse ES data not 
shown). A large proportion (~80%) of SMC cells derived from 
RA-treated O9 iPS cells changed their shape in response to 
carbachol treatment. No obvious response to carbachol was 
observed on cells derived from DMSO treatment (data not 
shown). Moreover, SMCs derived from O9 iPS and ES cells 
exhibited similar functional Ca2+ responses as confi rmed by 
real-time confocal imaging of Ca2+ release upon treatment 
with the potent vasoconstrictor caffeine (5 mmol/L, Fig. 4), 
endothelin (3 mmol/L) and the depolarization agent KCl (15 
mmol/L) (data not shown).
Discussion
Mouse ES cells have been used to study SMC differen-
tiation for decades. Previous studies by Drab et al. have 
shown that treatment of ES-derived embryoid bodies (EBs) 
with RA and dibutyryl-cyclic adenosine monophosphate 
could induce differentiation of spontaneously contracting 
SM-like cell clusters in 67% of EBs [10]. Also, Drab et al. 
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into SMC with the treatment of platelet-derived growth fac-
tor-BB [15,16]. However, because the lack of defi ned struc-
tural organization and positional information within EBs 
during pluripotent cell differentiation results in heteroge-
neity both within and between EBs, this method suffers 
characterized those SM-like cells as vascular SMC based on 
the expression of specifi c SMMHC isoforms and typical ion 
channels as well as the response to specifi c agonists with 
increased calcium [10]. Recently, FACS sorted Flk+ cells 

























d0 d3 d6 d9

















































d0 d3 d6 d9
FIG. 2. SMC-specifi c gene expression measured by qRT-PCR analyses in RA-induced differentiation of iPS and mouse 
ES cells. Total RNA was isolated from DMSO- or RA treatment–derived cells by Day 3, 6, and 9. The expression levels of 
SMC-specifi c genes included myocardin, SMMHC, SM22α, SM-α-actin, and smoothelin were determined. Values for mRNA 
levels normalized by 18S rRNA levels were expressed as mean ± SD (n = 3). Upper panel shows gene expression from O9 iPS 
cells, lower panel from CMTI-1 ES cells (mouse ES). Solid black bars represent the samples from DMSO-treated cells, hatched 
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sorting. This system is helpful not only to generate patient-
specifi c SMC in vitro, but to monitor the process of SMC 
differentiation.
Although both mouse ES and iPS cells can differentiate 
into SMCs in response to RA treatment, we observed differ-
ences in the process of differentiation of these two cell lines, 
as shown in Figs. 1 and 2. For example, the protein levels of 
SMMHC observed in iPS-derived SMCs after day 8 of RA 
treatment were lower than the levels observed in ES cell–
derived SMC (Fig. 1C). Moreover, the pattern and the levels 
of expression of myocardin and SMMHC mRNA were dif-
ferent between ES cell–derived and iPS-derived SMC (Fig. 
2). Previous studies have also shown that iPS cells possess 
difference from ES cells [16]. It is possible that these differ-
ences are due, at least in part, to an underlying regulation 
signaling pathway. Further studies are needed to address 
this question. In addition, TT025 and O9 iPS cells exhibited 
different responses to high concentration of RA. Although 
TT025 iPS cells died before day 4, O9 iPS cells were able to 
differentiate into SMCs. This different reaction may be due 
in part by the random insertion of those viral vectors of 
four transcriptional factors used for generation of iPS cells. 
Moreover, these differences suggest the requirement of 
comparison of multiple iPS cell lines, when iPS cells will be 
used for differentiation toward specifi c cell lineages in the 
current stage. Regardless of these uncertainties, generation 
of patient-matched pluripotent stem cells has the potential 
to address many of the current limitations observed in the 
treatment of SMC-related diseases. However, before iPS cells 
can be used as a cell resource for the treatment for cardio-
vascular disease, c-Myc upregulation during RA-induced 
differentiation, as observed in Supplementary Fig. S3, has 
to be paid more attention, given its tumorigenic feature. 
Several modifi ed protocols for the generation of iPS cells 
either without requirement of Myc retrovirus or using com-
bination small molecules with Oct4/Klf4 transfection have 
been recent developed, which will reduce the risk of tumor-
igenesis [23,24].
The strategy we have used here is simple, reproducible, 
and effi cient in generating SMCs in vitro from iPS and also 
mouse ES cells. The foresaid data suggest that 10−5 mol/L 
RA can drive iPS cells to differentiate into SMCs with high 
effi ciency. The reliable and reproducible iPS-SMC system 
described herein has remarkable potential for directly test-
ing the functional roles of candidate genes implicated in 
SMC differentiation and function. More importantly, this 
iPS-SMC system can be applied for individualized SMC gen-
eration for vascular tissue engineering, reconstruction, and 
personalized drug screening, given iPS pluripotency and 
potential immune privilege.
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diffi culties in cell-lineage manipulation and process mon-
itoring [17,18].
RA can induce differentiation of pluripotent cells into 
multiple cell lineages in a dose- and time-dependent manner, 
including skeletal muscle cell [19], neural cells (10−7 mol/L) 
[20], SMCs (10−9–10−6 mol/L) [10,21] and myocardial cells 
(10−9–10−8 mol/L) [22]. Our previous work has also shown that 
higher concentration of RA (10−5 mol/L) can induce human 
ES cells to differentiate into SMCs using monolayer culture 
[12]. Similar to mouse and human ES cells, in the current 
study, we document that RA (10−5 mol/L) can also induce iPS 
cells to differentiate into SMCs in vitro with high effi ciency. 
During this process, high concentration RA-treated mouse 
iPS and ES cells stably acquired SMC characteristics includ-
ing SMC specifi c contractile apparatus, transcriptional factor 
expression and calcium infl ux response to stimuli. Notably, 
this platform is EB-independent and does not involve cell 
FIG. 3. SMC-like cells derived from mouse iPS cells acquired 
the ability to contract in response to carbachol. SMC-like cells 
derived from mouse iPS cells after 10−5 mol/L RA treatment 
were rinsed with PBS and refreshed with culture medium. 
Upon addition of 1 mmol/L carbachol, pictures were taken 
at 10 s intervals for 10 min to document the morphological 
changes under the microscope. Upper panel shows cell con-
traction before and after carbachol treatment. The arrows 
indicate the contractile points. Lower panel shows cell contrac-
tion in response to carbachol is abolished with pretreatment 
of 10 μM atropine for 1 h.
08-SCD-2008_0179.indd   746 5/15/2009   3:12:38 PM
SMCs FROM iPS CELLS 747
References
 1.  Park IH, R Zhao, JA West, A Yabuuchi, H Huo, TA Ince , PH 
Lerou, MW Lensch and GQ Daley. (2008). Reprogramming 
of human somatic cells to pluripotency with defi ned factors. 
Nature 451:141–146.
 2.  Takahashi K and S Yamanaka. (2006). Induction of pluripotent 
stem cells from mouse embryonic and adult fi broblast cultures 
by defi ned factors. Cell 126:663–676.
 3.  Wernig M, A Meissner, R Foreman, T Brambrink, M Ku, K 
Hochedlinger, BE Bernstein and R Jaenisch. (2007). In vitro 
reprogramming of fi broblasts into a pluripotent ES-cell-like 
state. Nature 448:318–324.
 4.  Yu J, MA Vodyanik, K Smuga-Otto, J Antosiewicz-Bourget, 
JL Frane, S Tian, J Nie, GA Jonsdottir, V Ruotti, R Stewart, II 
Slukvin and JA Thomson. (2007). Induced pluripotent stem cell 
lines derived from human somatic cells. Science 318:1917–1920.
 5.  Hanna J, M Wernig, S Markoulaki, CW Sun, A Meissner, JP 
Cassady, C Beard, T Brambrink, LC Wu, TM Townes and R 
Jaenisch. (2007). Treatment of sickle cell anemia mouse model with 
iPS cells generated from autologous skin. Science 318:1920–1923.
 6.  Wernig M, JP Zhao, J Pruszak, E Hedlund, D Fu, F Soldner, V 
Broccoli, M Constantine-Paton, O Isacson and R Jaenisch. (2008). 
Neurons derived from reprogrammed fi broblasts functionally 
integrate into the fetal brain and improve symptoms of rats with 
Parkinson’s disease. Proc Natl Acad Sci USA 105:5856–5861.
 7.  Owens GK, MS Kumar and BR Wamhoff. (2004). Molecular reg-
ulation of vascular smooth muscle cell differentiation in devel-
opment and disease. Physiol Rev 84:767–801.
 8.  Parmacek MS. (2001). Transcriptional programs regulating vas-
cular smooth muscle cell development and differentiation. Curr 
Top Dev Biol 51:69–89.
 9.  Long X, EE Creemers, DZ Wang, EN Olson and JM Miano. 
(2007). Myocardin is a bifunctional switch for smooth ver-
sus skeletal muscle differentiation. Proc Natl Acad Sci USA 
104:16570–16575.
10.  Drab M, H Haller, R Bychkov, B Erdmann, C Lindschau, H 
Haase, I Morano, FC Luft and AM Wobus. (1997). From totipo-
tent embryonic stem cells to spontaneously contracting smooth 
muscle cells: a retinoic acid and db-cAMP in vitro differentia-
tion model. FASEB J 11:905–915.
11.  Sinha S, BR Wamhoff, MH Hoofnagle, J Thomas, RL Neppl, T 
Deering, BP Helmke, DK Bowles, AV Somlyo and GK Owens. 
(2006). Assessment of contractility of purifi ed smooth mus-
cle cells derived from embryonic stem cells. Stem Cells 
24:1678–1688.
12.  Huang H, X Zhao, L Chen, C Xu, X Yao, Y Lu, L Dai and M 
Zhang. (2006). Differentiation of human embryonic stem 
cells into smooth muscle cells in adherent monolayer culture. 
Biochem Biophys Res Commun 351:321–327.
13.  Xie CQ, J Zhang, L Villacorta, T Cui, H Huang and YE Chen. 
(2007). A highly effi cient method to differentiate smooth muscle 
cells from human embryonic stem cells. Arterioscler Thromb 
Vasc Biol 27:e311–e312.
14.  Wamhoff BR, JL Dixon and M Sturek. (2002). Atorvastatin treat-
ment prevents alterations in coronary smooth muscle nuclear 
Ca2+ signaling in diabetic dyslipidemia. J Vasc Res 39:208–220.
15.  Yamashita J, H Itoh, M Hirashima, M Ogawa, S Nishikawa, 
T Yurugi, M Naito, K Nakao and S Nishikawa. (2000). Flk1-
positive cells derived from embryonic stem cells serve as vas-
cular progenitors. Nature 408:92–96.
16.  Schenke-Layland K, KE Rhodes, E Angelis, Y Butylkova, S 
Heydarkhan-Hagvall, C Gekas, R Zhang, JI Goldhaber, HK 
Mikkola, K Plath and WR Maclellan. (2008). Reprogrammed 
mouse fi broblasts differentiate into cells of the cardiovascular 
and hematopoietic lineages. Stem Cells 26:1537–1546.
17.  Zhang H, K Saeki, A Kimura, K Saeki, M Nakahara, M Doshi, 
Y Kondo, T Nakano and A Yuo. (2006). Effi cient and repeti-
tive  production of hematopoietic and endothelial cells from 
 feeder-free monolayer culture system of primate embryonic 
stem cells. Biol Reprod 74:295–306.
18.  Rathjen J and PD Rathjen. (2001). Mouse ES cells: experimental 
exploitation of pluripotent differentiation potential. Curr Opin 
Genet Dev 11:587–594.
19.  Dinsmore J, J Ratliff, T Deacon, P Pakzaban, D Jacoby, W 
Galpern and O Isacson. (1996). Embryonic stem cells differen-
tiated in vitro as a novel source of cells for transplantation. Cell 
Transplant 5:131–143.
FIG. 4. Functional characteristics of SMCs derived from iPS cells. Measurement of calcium transients before and after 
treatment with the vasoactive agonist (5 mmol/L caffeine). Fluorescence intensity was monitored in cells loaded with Fluo-4 
AM with confocal microscope (LSM 510 Meta, Carl Zeiss MicroImaging Inc.). The color lines in the right panel correspond to 
the fl uorescence changes in the cells indicated by the same color circles in the left panel. The inserted graph shows the fl uo-





































0 10 20 30 40 50 60 70 80 90
08-SCD-2008_0179.indd   747 5/15/2009   3:12:39 PM
XIE ET AL.748
Address reprint requests to:
Dr. Y. Eugene Chen
Cardiovascular Center
Department of Internal Medicine
University of Michigan Medical Center








People’s Republic of China
E-mail: zhangming_ls@zju.edu.cn
Received for publication June 30, 2008
Accepted after revision September 16, 2008
Prepublished on Liebert Instant Online September 16, 2008
20.  Bain G, D Kitchens, M Yao, JE Huettner and DI Gottlieb. (1995). 
Embryonic stem cells express neuronal properties in vitro. Dev 
Biol 168:342–357.
21.  Manabe I and GK Owens. (2001). Recruitment of serum response 
factor and hyperacetylation of histones at smooth muscle-spe-
cifi c regulatory regions during differentiation of a novel P19-
derived in vitro smooth muscle differentiation system. Circ Res 
88: 1127–1134.
22.  Wobus AM, K Guan, HT Yang and KR Boheler. (2002). 
Embryonic stem cells as a model to study cardiac, skeletal mus-
cle, and vascular smooth muscle cell differentiation. Methods 
Mol Biol 185:127–156.
23.  Nakagawa M, M Koyanagi, K Tanabe, K Takahashi, T Ichisaka, 
T Aoi, K Okita, Y Mochiduki, N Takizawa and S Yamanaka. 
(2008). Generation of induced pluripotent stem cells with-
out Myc from mouse and human fi broblasts. Nat Biotechnol 
26:101–106.
24.  Shi Y, JT Do, C Desponts, HS Hahm, HR Schöler and S Ding. 
(2008). A combined chemical and genetic approach for the 
generation of induced pluripotent stem cells. Cell Stem Cells 
2:525–528.
08-SCD-2008_0179.indd   748 5/15/2009   3:12:39 PM
This article has been cited by:
1. Jeffrey A. Beamish , Ping He , Kandice Kottke-Marchant , Roger E. Marchant . 2010. Molecular Regulation of Contractile Smooth
Muscle Cell Phenotype: Implications for Vascular Tissue EngineeringMolecular Regulation of Contractile Smooth Muscle Cell
Phenotype: Implications for Vascular Tissue Engineering. Tissue Engineering Part B: Reviews 16:5, 467-491. [Abstract] [Full
Text] [PDF] [PDF Plus]
2. Elaine Vo, Donny Hanjaya-Putra, Yuanting Zha, Sravanti Kusuma, Sharon Gerecht. 2010. Smooth-Muscle-Like Cells Derived
from Human Embryonic Stem Cells Support and Augment Cord-Like Structures In Vitro. Stem Cell Reviews and Reports 6:2,
237-247. [CrossRef]
3. Reiesha D Robbins, Nutan Prasain, Bernhard F Maier, Mervin C Yoder, Raghavendra G Mirmira. 2010. Inducible pluripotent
stem cells: not quite ready for prime time?. Current Opinion in Organ Transplantation 15:1, 61-67. [CrossRef]
4. Soo Seung Choi. 2010. Effect of pH Change on Vascular Smooth Muscle Contractility in Rat Superior Mesenteric Artery and
Its Branches. The Korean Journal of Thoracic and Cardiovascular Surgery 43:4, 345. [CrossRef]
5. Hong-Fen SHEN, Zhi-Fang YAO, Gao-Fang XIAO, Jun-Shuang JIA, Dong XIAO, Kai-Tai YAO. 2009. Induced Pluripotent
Stem Cells(iPS Cells):Current Status and Future Prospect*. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS 2009:8,
950-960. [CrossRef]
